{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:13:04Z","timestamp":1788297184027,"version":"build-2803163510"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.7759\/cureus.115609","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:15:25Z","timestamp":1788293725000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Dermatologic Toxicity During Amivantamab-Lazertinib Treatment in Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer"],"prefix":"10.7759","author":[{"given":"Chloe M","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M","family":"Delancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Bonawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang YL","year":"2016","unstructured":"Zhang YL, Yuan JQ, Wang KF, et al.. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016, 7:78985-93. 10.18632\/oncotarget.12587","journal-title":"Oncotarget"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.07.117","article-title":"Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial","volume":"20","author":"Cho BC","year":"2025","unstructured":"Cho BC, Li W, Spira AI, et al.. Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: the COCOON global randomized controlled trial. J Thorac Oncol. 2025, 20:1517-30. 10.1016\/j.jtho.2025.07.117","journal-title":"J Thorac Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho BC","year":"2024","unstructured":"Cho BC, Lu S, Felip E, et al.. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2024, 391:1486-98. 10.1056\/NEJMoa2403614","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol33020096","article-title":"Prevention and management of dermatologic adverse events in patients treated with amivantamab plus lazertinib","volume":"33","author":"Szwed C","year":"2026","unstructured":"Szwed C, Blicharz L, Knetki-Wroblewska M, Rudnicka L, Czuwara J. Prevention and management of dermatologic adverse events in patients treated with amivantamab plus lazertinib. Curr Oncol. 2026, 33:96. 10.3390\/curroncol33020096","journal-title":"Curr Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2026.0017","article-title":"Non-small cell lung cancer, version 4.2026, NCCN Clinical Practice Guidelines In Oncology","volume":"24","author":"Riely GJ","year":"2026","unstructured":"Riely GJ, Wood DE, Aisner DL, et al.. Non-small cell lung cancer, version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026, 24:10.6004\/jnccn.2026.0017","journal-title":"J Natl Compr Canc Netw"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a\u00a0secondary analysis from MARIPOSA","volume":"35","author":"Felip E","year":"2024","unstructured":"Felip E, Cho BC, Guti\u00e9rrez V, et al.. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a\u00a0secondary analysis from MARIPOSA. Ann Oncol. 2024, 35:805-16. 10.1016\/j.annonc.2024.05.541","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpccr.2023.100273","article-title":"Severe scalp ulcerations and granulomata during treatment with amivantamab","volume":"13","author":"Zhou JJ","year":"2024","unstructured":"Zhou JJ, Chen LN, Lehan T, et al.. Severe scalp ulcerations and granulomata during treatment with amivantamab. Curr Probl Cancer Case Rep. 2024, 13:10.1016\/j.cpccr.2023.100273","journal-title":"Curr Probl Cancer Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/526910-severe-dermatologic-toxicity-during-amivantamab-lazertinib-treatment-in-epidermal-growth-factor-receptor-egfr-mutated-non-small-cell-lung-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:15:26Z","timestamp":1788293726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/526910-severe-dermatologic-toxicity-during-amivantamab-lazertinib-treatment-in-epidermal-growth-factor-receptor-egfr-mutated-non-small-cell-lung-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.115609","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}